sb 203580 has been researched along with astragaloside a in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (astragaloside a) | Trials (astragaloside a) | Recent Studies (post-2010) (astragaloside a) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 675 | 5 | 573 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, C; Li, G; Li, X; Niu, Y; Wang, X; Xing, G; Zhou, L | 1 |
1 other study(ies) available for sb 203580 and astragaloside a
| Article | Year |
|---|---|
Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p38 MAPK pathway.
Topics: Animals; Collagen; Extracellular Matrix; Hepatic Stellate Cells; Humans; Imidazoles; Lipid Peroxidation; Liver Cirrhosis; MAP Kinase Signaling System; NF-E2-Related Factor 2; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Primary Cell Culture; Pyridines; Rats; Reactive Oxygen Species; Saponins; Triterpenes | 2013 |